A Clinical Trial to Investigate Biomarker Effects of Pre-Surgical Treatment With DDR Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) Who Are Planned to Undergo Surgery That is Likely to be Followed by Radiotherapy and/or Chemotherapy
Phase of Trial: Phase I
Latest Information Update: 09 Apr 2018
At a glance
- Drugs AZD 6738 (Primary) ; Olaparib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Biomarker; Pharmacodynamics
- Sponsors AstraZeneca
- 03 Jan 2018 Planned End Date changed from 9 Oct 2019 to 3 Sep 2019.
- 03 Jan 2018 Planned primary completion date changed from 9 Oct 2019 to 3 Sep 2019.
- 28 Nov 2017 Status changed from not yet recruiting to recruiting.